Effect of COV2 vaccine formulation on the ability to generate antibodies against coronavirus

2025-523712-37-00 Protocol COV2FIN12 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 21 Jan 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol COV2FIN12

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 20
Countries 1
Sites 1

Booster immunisation against COVID-19 disease caused by SARS-COV-2 Virus

Key facts

Sponsor
Rokote Laboratories Finland Oy
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
21 Jan 2026 → ongoing
Decision date (initial)
2025-12-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523712-37-00
WHO UTN
U1111-1328-8612

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Booster immunisation against COVID-19 disease caused by SARS-COV-2 Virus

VersionLevelCodeTermSystem organ class
28.0 LLT 10084462 SARS-CoV-2 vaccination 100000004865
28.0 LLT 10087820 Vaccination booster dose 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Rokote Laboratories Finland Oy

Sponsor organisation
Rokote Laboratories Finland Oy
Address
Microkatu 1
City
Kuopio
Postcode
70210
Country
Finland

Scientific contact point

Organisation
Rokote Laboratories Finland Oy
Contact name
CEO

Public contact point

Organisation
Rokote Laboratories Finland Oy
Contact name
CEO

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ongoing, recruitment ended 20 1
Rest of world 0

Investigational sites

Finland

1 site · Ongoing, recruitment ended
Pohjois-Savon hyvinvointialue
Kuopio University Hospital, Department of Otorhinolaryngology, Puijonlaaksontie 2, P. O. Box 1711, Kuopio

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2026-01-21 2026-02-10 2026-05-19

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-22 Finland Acceptable
2025-12-04
2025-12-17